The present disclosure is directed generally to treatment devices with delivery-activated inflatable members, and associated systems and methods for treating the spinal cord and other tissues.
Neurological stimulators have been developed to treat pain, movement disorders, functional disorders, spasticity, cancer, cardiac disorders, and several other medical conditions. Implantable neurological stimulation systems generally have an implantable pulse generator and one or more electrode leads that deliver electrical pulses to neurological tissue or muscle tissue. For example, several neurological stimulation systems for spinal cord stimulation (SCS) have cylindrical leads that include a lead body with a circular cross-sectional shape and one or more conductive rings spaced apart from each other at the distal end of the lead body. The conductive rings operate as individual electrodes. In many cases, the SCS leads are implanted percutaneously through a large needle inserted into the epidural space, with or without the assistance of a stylet. One concern of such leads is that the leads may not remain in the desired position after being implanted. This is undesirable because, if the leads migrate from the initial implantation site, the stimulation provided by the electrodes may no longer be directed to the appropriate target tissue. Accordingly, the efficacy of the treatment can be significantly compromised.
Another type of stimulation lead is a paddle lead. Paddle leads typically have a relatively flat body with electrodes arranged on one side of the body. Paddle leads are commonly used for cortical stimulation and SCS applications. Large paddle leads are desirable because they cover more neurological structures and, in at least some cases, may be more stable and less subject to migration than cylindrical leads. However, large paddle leads are not well suited to percutaneous implantation. As a result, large paddle leads are often surgically implanted using highly invasive procedures that are costly and can lead to patient complications.
Specific details of several embodiments of the disclosure are described below with reference to implantable leads for stimulating neural structures, methods for implanting leads, methods for manufacturing leads, and methods for stimulating a target neural site of a patient. Although selected embodiments are described below with respect to stimulating the dorsal root and/or neighboring regions of the spinal column to control pain, the leads may be used for stimulating the brain, peripheral neurological structures, and/or other tissue (e.g., muscle tissue). Several embodiments can have different configurations, components or procedures than those described in this section, and other embodiments may eliminate particular components or procedures. A person of ordinary skill in the relevant art, therefore, will understand that the invention may have other embodiments with additional elements, and/or may have other embodiments without several of the features shown and described below with reference to
A patient treatment system in accordance with a particular embodiment of the disclosure includes a lead body having an opening and an inner surface positioned around the opening. An inflatable member is carried by the lead body, and the inflatable member and/or the lead body include a frangible portion accessible from the opening. The inflatable member has an expandable interior volume bounded at least in part by the frangible portion. A delivery device is received in the opening of the lead body and is positioned to open a passage through the frangible portion between the interior volume of the inflatable member and the opening of the lead body when the delivery device is removed from the opening of the lead body. Accordingly, the delivery device can be used to position the lead body at the appropriate location in a patient and then, as the delivery device is removed from the lead body, it can open up communication between the inflatable member and the opening in the lead body. The inflatable member can be filled with a self-expanding material, so that it “automatically” inflates once the frangible portion has been broken. In another arrangement, a fluid can be driven into the inflatable member via the opening to inflate or further inflate the inflatable member. The lead body can have one or more electrical contacts that provide electrical stimulation to the patient, while the inflatable member secures or assists in securing the lead body at the appropriate patient location.
A representative method for positioning a lead in a patient includes percutaneously passing a lead into the patient's body while the lead is carried by a delivery device. The lead can have an inflatable volume, and the delivery device can be received in an opening of the lead. The method can further include forming a passage between the opening of the lead and the inflatable volume by at least partially removing the delivery device from the opening. The inflatable volume can then be expanded. In particular embodiments, forming the passage between the opening in the lead and the inflatable volume can include tearing a wall between the opening and the inflatable volume as the delivery device is removed. In a particular arrangement, an adhesive connection between the lead and the delivery device is broken as the delivery device is removed. In another embodiment, the delivery device can include a barb or other sharpened member that penetrates the wall between the opening in the lead and the inflatable volume as the delivery device is removed.
Yet another aspect of the disclosure includes a method for manufacturing a patient treatment device. A representative method includes positioning a delivery device proximate to a lead body and juxtaposing the delivery device and the lead body with the delivery device located within an opening of the lead body. The delivery device is positioned so that removing the delivery device from the opening forms a fluid passage between the opening and an interior volume of an expandable member carried by the lead body. The lead body can accordingly be adhered to the delivery device in one arrangement. The expandable member can be collapsed and/or evacuated prior to being attached to the delivery device, or it (along with an interior self-expanding material) can be collapsed around the delivery device while the delivery device is positioned within the lead body.
The pulse generator 101 can transmit signals to the lead body 110 that up-regulate (e.g., stimulate) and/or down-regulate (e.g., block) target nerves. Accordingly, the pulse generator 101 can include a computer-readable medium containing instructions for generating and transmitting suitable therapy signals. The pulse generator 101 and/or other elements of the system 100 can include one or more processors, memories, and/or input/output devices. The pulse generator 101 can include multiple portions, e.g., for directing signals in accordance with multiple signal delivery parameters, housed in a single housing (as shown in
In some embodiments, the pulse generator 101 can obtain power to generate the therapy signals from an external power source 103. The external power source 103 can transmit power to the implanted pulse generator 101 using electromagnetic induction (e.g., RF signals). For example, the external power source 103 can include an external coil 104 that communicates with a corresponding internal coil (not shown) within the implantable pulse generator 101. The external power source 103 can be portable for ease of use.
In another embodiment, the pulse generator 101 can obtain the power to generate therapy signals from an internal power source. For example, the implanted pulse generator 101 can include a non-rechargeable battery or a rechargeable battery to provide such power. When the internal power source includes a rechargeable battery, the external power source 103 can be used to recharge the battery. The external power source 103 can in turn be recharged from a suitable power source (e.g., conventional wall power).
In still further embodiments, an external programmer (not shown) can communicate with the implantable pulse generator 101 via electromagnetic induction. Accordingly, a practitioner can update the therapy instructions provided by the pulse generator 101. Optionally, the patient may also have control over at least some therapy functions, e.g., starting and/or stopping the pulse generator 101.
The system 100 can further include one or more inflatable and/or expandable members 130 (two are shown in solid lines in
The degree (if any) to which the inflatable members 130 apply a force to the patient tissue 192 can be selected depending upon the characteristics of the particular implantation site. For example, if the inflatable members 130 carry electrodes 113 and are positioned so that the electrodes 113 contact target neural sites (e.g., neurons), then it may be desirable to arrange the inflatable members 130 so that the electrodes 113 touch and/or mate with the adjacent tissue, but do not apply a significant force to the adjacent tissue, so as to avoid creating a patient sensation and/or other potentially undesirable side effect. In another embodiment, for example, if the electrodes 113 are spaced apart from the inflatable members 130, the inflatable members 130 can apply some force to the tissue 192 to secure the lead body 110 in position. For example, if the inflatable members 130 bear against bony tissue or other tissue that is less sensitive than neural tissue, it may be acceptable to both patient and practitioner to have the inflatable members 130 apply some (e.g., low level) force to the tissue.
In one aspect of the arrangement described above with reference to
One feature of at least some of the foregoing embodiments is that the lead body can include one or more inflatable or otherwise expandable members having frangible portions that are opened as the associated delivery device is removed from the lead body. An advantage of this arrangement is that it can allow the inflatable member to have a collapsed (e.g., low-profile) shape as it is delivered into the patient's body, and an expanded shape (e.g., one that can secure the lead body in position) once the delivery tool has been removed. In particular embodiments, the inflatable member can assume the expanded shape automatically, e.g., when the inflatable member includes a self-inflating material and when the frangible portion is disrupted such that fluid can fill or at least partially fill the self-inflating material during inflation. This particular arrangement can reduce the number of tasks a practitioner performs when fixing or at least partially fixing the lead body in position in the patient's body. Another expected advantage of this particular arrangement is that the self-inflating material does not require continuous fluid pressure for the inflatable member to retain its expanded shape. Accordingly, the practitioner need not seal the inflatable member after it has expanded, and, if the inflatable member develops a leak (e.g., at its exterior surface), it can still retain its expanded shape.
From the foregoing, it will be appreciated that specific embodiments of the disclosure have been described herein for purposes of illustration, but that various modifications may be made without deviating form the disclosure. For example, the lead bodies may have arrangements other than those specifically shown and discussed above, including flatter or otherwise non-isodiametric cross-sectional shapes. As noted above, the lead body can be connected directly to an implanted pulse generator, or an additional signal communication link can be connected between the lead body and the implanted pulse generator. The lead body can include any of a variety of support structures that carry the appropriate signal delivery elements. Such elements can include electrical contacts, as discussed above, or other elements (e.g., ultrasonic or optical elements). Any of these elements may be carried by the inflatable member(s) and/or by other portions of the lead body. The inflatable members can extend around a portion of the perimeter of the lead body (as shown in
Certain aspects of the disclosure described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, the barb or other sharpened element described above with reference to
This application is a divisional application of U.S. patent application Ser. No. 12/104,230, filed on Apr. 16, 2008, now U.S. Pat. No. 8,326,439 and entitled “TREATMENT DEVICES WITH DELIVERY-ACTIVATED INFLATABLE MEMBERS, AND ASSOCIATED SYSTEMS and METHODS FOR TREATING THE SPINAL CORD AND OTHER TISSUES,” which is incorporated herein in its entirety by reference.
Number | Name | Date | Kind |
---|---|---|---|
3738368 | Avery et al. | Jun 1973 | A |
4136703 | Wittkampf | Jan 1979 | A |
4282886 | King | Aug 1981 | A |
4519403 | Dickhudt | May 1985 | A |
5052375 | Stark et al. | Oct 1991 | A |
5143090 | Dutcher et al. | Sep 1992 | A |
5211165 | Dumoulin et al. | May 1993 | A |
5251634 | Weinberg | Oct 1993 | A |
5325873 | Hirschi et al. | Jul 1994 | A |
5425367 | Shapiro et al. | Jun 1995 | A |
5484445 | Knuth et al. | Jan 1996 | A |
5527358 | Mehmanesh et al. | Jun 1996 | A |
5549555 | Sohn | Aug 1996 | A |
5549662 | Fordenbacher | Aug 1996 | A |
5728148 | Bostrom et al. | Mar 1998 | A |
5741319 | Woloszko et al. | Apr 1998 | A |
5782898 | Dahl et al. | Jul 1998 | A |
5846196 | Siekmeyer et al. | Dec 1998 | A |
5964730 | Williams et al. | Oct 1999 | A |
6024702 | Iversen | Feb 2000 | A |
6038480 | Hrdlicka et al. | Mar 2000 | A |
6041259 | Agarwala et al. | Mar 2000 | A |
6132561 | Mincher et al. | Oct 2000 | A |
6161047 | King et al. | Dec 2000 | A |
6163727 | Errico | Dec 2000 | A |
6192278 | Werner et al. | Feb 2001 | B1 |
6205361 | Kuzma et al. | Mar 2001 | B1 |
6319241 | King et al. | Nov 2001 | B1 |
6325778 | Zadno-Azizi et al. | Dec 2001 | B1 |
6487446 | Hill et al. | Nov 2002 | B1 |
6510347 | Borkan | Jan 2003 | B2 |
6697676 | Dahl et al. | Feb 2004 | B2 |
6704605 | Soltis et al. | Mar 2004 | B2 |
6714822 | King et al. | Mar 2004 | B2 |
6746474 | Saadat | Jun 2004 | B2 |
6758854 | Butler et al. | Jul 2004 | B1 |
6795737 | Gielen et al. | Sep 2004 | B2 |
6832115 | Borkan | Dec 2004 | B2 |
6853862 | Marchal et al. | Feb 2005 | B1 |
6895283 | Erickson et al. | May 2005 | B2 |
6909918 | Stypulkowski | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6920359 | Meadows et al. | Jul 2005 | B2 |
6934589 | Sundquist et al. | Aug 2005 | B2 |
6944501 | Pless | Sep 2005 | B1 |
6961621 | Krishnan et al. | Nov 2005 | B2 |
6999819 | Swoyer et al. | Feb 2006 | B2 |
7054690 | Imran | May 2006 | B2 |
7099718 | Thacker et al. | Aug 2006 | B1 |
7177702 | Wallace et al. | Feb 2007 | B2 |
7182783 | Trieu | Feb 2007 | B2 |
7184842 | Seifert et al. | Feb 2007 | B2 |
7187982 | Seifert et al. | Mar 2007 | B2 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7200446 | Borkan | Apr 2007 | B2 |
7276057 | Gerber | Oct 2007 | B2 |
7379776 | Chitre et al. | May 2008 | B1 |
7769472 | Gerber | Aug 2010 | B2 |
7797054 | Skubitz et al. | Sep 2010 | B2 |
7822482 | Gerber | Oct 2010 | B2 |
7856277 | Thacker et al. | Dec 2010 | B1 |
7983766 | Thacker et al. | Jul 2011 | B1 |
7996055 | Hauck et al. | Aug 2011 | B2 |
8092456 | Bleich et al. | Jan 2012 | B2 |
8128600 | Gill | Mar 2012 | B2 |
8326439 | Boling et al. | Dec 2012 | B2 |
20010053885 | Gielen et al. | Dec 2001 | A1 |
20020019627 | Maguire et al. | Feb 2002 | A1 |
20020147486 | Soukup et al. | Oct 2002 | A1 |
20020156513 | Borkan | Oct 2002 | A1 |
20030062048 | Gradon et al. | Apr 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030136418 | Behm | Jul 2003 | A1 |
20040097803 | Panescu | May 2004 | A1 |
20050065588 | Zhao et al. | Mar 2005 | A1 |
20050075684 | Phillips et al. | Apr 2005 | A1 |
20050203599 | Garabedian et al. | Sep 2005 | A1 |
20060206183 | Pyles et al. | Sep 2006 | A1 |
20060247569 | Bertrand et al. | Nov 2006 | A1 |
20060259110 | Wallace et al. | Nov 2006 | A1 |
20060282121 | Payne et al. | Dec 2006 | A1 |
20060282123 | Hunter et al. | Dec 2006 | A1 |
20070027514 | Gerber | Feb 2007 | A1 |
20070027515 | Gerber | Feb 2007 | A1 |
20070106339 | Errico et al. | May 2007 | A1 |
20070135881 | Vilims | Jun 2007 | A1 |
20070167992 | Carley | Jul 2007 | A1 |
20070255365 | Gerber et al. | Nov 2007 | A1 |
20080027505 | Levin et al. | Jan 2008 | A1 |
20080046036 | King et al. | Feb 2008 | A1 |
20080103576 | Gerber | May 2008 | A1 |
20080103578 | Gerber | May 2008 | A1 |
20080103579 | Gerber | May 2008 | A1 |
20080103580 | Gerber | May 2008 | A1 |
20080140152 | Imran et al. | Jun 2008 | A1 |
20080183257 | Imran et al. | Jul 2008 | A1 |
20100292769 | Brounstein et al. | Nov 2010 | A1 |
20110029056 | Skubitz et al. | Feb 2011 | A1 |
20110031961 | Durand et al. | Feb 2011 | A1 |
20110166621 | Cowan et al. | Jul 2011 | A1 |
20110167630 | Heruth et al. | Jul 2011 | A1 |
20110184488 | De Ridder | Jul 2011 | A1 |
20110202097 | Bonde et al. | Aug 2011 | A1 |
20110224682 | Westlund et al. | Sep 2011 | A1 |
20110224710 | Bleich | Sep 2011 | A1 |
20110230943 | Johnson et al. | Sep 2011 | A1 |
20120083709 | Parker et al. | Apr 2012 | A1 |
Number | Date | Country |
---|---|---|
WO-2008094952 | Aug 2008 | WO |
Entry |
---|
International Search Report and Written Opinion, International Application No. PCT/US08/40700, Applicant: Nevro Corporation, mailed Jun. 9, 2009, 11 pages. |
Number | Date | Country | |
---|---|---|---|
20130144305 A1 | Jun 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12104230 | Apr 2008 | US |
Child | 13678435 | US |